Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients

Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Med Oncol
Hlavní autoři: Buda-Nowak, Anna, Kucharz, Jakub, Dumnicka, Paulina, Kuzniewski, Marek, Herman, Roman Maria, Zygulska, Aneta L., Kusnierz-Cabala, Beata
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2017
Témata:
Original Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5366170/
https://ncbi.nlm.nih.gov/pubmed/28343336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-0928-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky